Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech
Apr 01, 2015, 08:45 ET
BALTIMORE, Apr. 1, 2015 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
In the article on the Company, analyst Rob Goldman outlines the impact the current M&A environment and the Company's standing.
"The market is in the midst of a flurry of biotech M&A and PharmaCyte Biotech may be sitting in the catbird seat as an unusually attractive potential target. After all, major pharmaceutical companies are in panic mode. They are staring in the face of patent expirations on key products representing hundreds of millions or billions in revenue on one side, and competition for their big sellers from peers and upstarts in mid-late stage clinical trials on the other side. To fend off these attacks, management teams have entered into a quasi-arms race in their quest to rapidly add companies via acquisition that complement their current therapeutic categories. For example, Teva Pharmaceutical is buying Auspex Pharmaceutical for more than $3 billion, which represents a 50% premium to the previous day's close for a non-revenue generating company with products in a series of clinical trials."
Goldman further noted, "Since the Company's Cell-in-a-Box(R) live cell encapsulation technology has such broad potential applications, it could emerge as a universal therapy for the treatment of multiple forms of cancer and diabetes and compete with a number of existing, billion dollar products, potentially making PharmaCyte Biotech the prototypical acquisition target."
"Most early stage and mid-stage companies such as PharmaCyte Biotech are keenly aware of big pharma's desire to acquire firms with unique technology that can potentially treat diseases representing billions in market opportunity, and are therefore wisely built for potential sale. As a result, early and mid-stage clinical trials are designed not just for maximum efficacy and safety but to attract the attention of the world's biggest pharmaceutical players. With three separate clinical trials this year featuring its proprietary technology, PharmaCyte Biotech could be high on the industry's radar screen once the trials are completed and the results are released."
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was recently compensated by a third party in the amount of $4000 for investment research services and has been compensated $2500 for the publication of a series of articles.
About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.
Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]
SOURCE Goldman Small Cap Research